In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Agenus, with a price target of $23.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Emily Bodnar has given her Buy rating due to a combination of factors including the promising progress in Agenus’s clinical trials and strategic partnerships. The company is advancing its botensilimab and balstilimab (bot/bal) development, with a Phase 3 trial set to begin in the fourth quarter of 2025. This trial, known as BATTMAN, aims to address the growing incidence of colorectal cancer, a significant health concern globally.
Furthermore, Agenus’s collaboration with the Canadian Cancer Trials Group (CCTG) is expected to facilitate efficient patient enrollment, leveraging CCTG’s extensive experience in conducting large international trials. The trial’s design, including a 1:1 randomization against best supportive care, has received FDA approval, enhancing its credibility. The anticipated outcomes of these trials, along with the strategic international partnerships, underpin Bodnar’s confidence in the company’s potential for growth, justifying the Buy rating.
Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, Agios Pharma, and NovoCure. According to TipRanks, Bodnar has an average return of -2.7% and a 33.16% success rate on recommended stocks.